Liquid biopsy testing
Patients with advanced NSCLC may not be healthy enough for a tissue biopsy, or might only be able to undergo limited tissue procedures, like a Fine Needle Aspirate (FNA) or Core Needle Biopsy (CNB) for diagnosis.
After first line TKI therapy, it is preferable to use a new tumour specimen for EGFR analysis though this would require another invasive tissue biopsy procedure. The key benefits of testing with plasma is that it involves a non-invasive procedure for collecting biopsy from the patient and it can be sampled as frequently as needed without putting patients at risk.
cfDNA EGFR testing
At Lab21 we are now offering cfDNA EGFR testing from blood on the Roche Cobas platform. The assay covers the following:
- Detects 42 mutations in exons 18, 19, 20 and 21 of the EGFR gene including the T790M resistant mutation
- Provides consistent, objective and reproducible results from laboratory to laboratory
- Ensures clinicians are given accurate results to support patient management
- Results returned within 5 working days from sample receipt
When testing plasma with the cobas® EGFR Mutation Test v2, a feature called the Semi-Quantitative Index (SQI)* is included in the report—this number is designed to reflect a trend in the EGFR mutation load. If frequently testing a patient for the EGFR mutation, tracking the SQI value and identifying a trend may lead to understanding tumour progression, an option not available in other tests.
To request cfDNA EGFR testing, please contact the Lab 21 Customer Services Team for further information regarding requesting the test and pricing.
Not provided under our UKAS accreditation.
Please see our Accreditation page for full scope of accredited testing.